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Health is the objective of all. Centuries and decades 
ago, people looked for treatment for acute diseases, es-
pecially infectious one, and to lesser extent for chronic 
diseases. Currently and according to the World Health 
Organization, health is a state of complete physical, 
mental, and social well-being, not merely the absence 
of disease or infirmity [1]. General population health 
demands have progressively increased over the last few 
years. People not only look for treatment for all dis-
eases, including degenerative diseases related to aging, 
but ask for prophylactic treatment against all diseases 
including cancer.
In Western Countries, cancer is the current leading 
cause of death. Many year ago, free radicals were 
identified as the main cancer risk factors [2]. The idea 
was well received by the scientific communities and 
the general population. Worldwide, the consumption 
of antioxidants in tablets and capsules is increasing, 
however and unfortunately cancer incidence continues 
rising. The one daily table of antioxidant, instead of 
consumption of green vegetables and fresh fruits, did 
not reduce cancer incidence.
Hepatitis B virus infections are known as the “silent epi-
demic” because many people infected don’t experience 
symptoms until decades later when they develop cirrho-
sis or hepatocellular carcinoma. Currently, hepatitis B 
vaccine is included in the vaccine calendar of all Euro-
pean Countries and USA. The vaccine coverage is very 
high and many adults have been vaccinated over the 
last years. This shows that most of Western Countries 
citizens have accepted hepatitis B vaccine as an effec-
tive protective measure against hepatitis, cirrhosis and 
hepatocellular carcinoma. Curiously, many health care 
workers do not adopt the protective measures against 
hepatitis B infection and feel protected after receiving 
the 3 doses of hepatitis B vaccine.
Cervical cancer is one of the most prevalent and ag-
gressive cancers among women. Most of cases were 
attributed to Human Papilloma Virus (HPV) infection. 
Recently, a vaccine against the most prevalent carcino-
genic HPV genotypes (16 and 18) has been developed. 
The available studies about this vaccine show that it 
protects against these 2 carcinogenic genotypes of 
HPV for at least 5 years. Till date no study has demon-
strated its effectiveness against cervical cancer on long 
term (20 years after vaccination). Social conservatives 
say that immunizing teenagers could encourage sexual 
activity. The mass application of the vaccine could 
give false impression of protection against sexually 
transmitted diseases like gonorrhea, syphilis and HIV.
Epstein-Barr virus (EBV) usually causes no health prob-
lems, but the virus was associated with certain kinds 
of cancer, including lymphomas and naso-pharyngeal 
carcinoma [3]. Recently, several clinical trials have been 
conducted to evaluate the efficacy of a new vaccine 
against EBV. It is assumed that this vaccine could pro-
tect individuals against EBV infection and hence pre-
sumably reduce the burden of EBV-associated cancers 
by stimulating the body’s natural defences [4, 5].
Of no doubt cigarette smoking is the main risk factor 
for most malignant diseases especially lung cancer, the 
first killing malignancy worldwide. Cigarette smoking 
causes 87% of lung cancer deaths and is responsible 
for most cancers of the larynx, oral cavity and pharynx, 
oesophagus, and bladder. These facts about the haz-
ards of cigarette smoking are well known by most of 
the general population in Western Countries. In 2005, 
24% of adults aged 16 or over in Great Britain smoked 
cigarettes, indicating a slight fall in the prevalence of 
smoking among both men and women since the late 
1990s [6]. This unexplained high prevalence of smok-
ing demonstrates clearly the discrepancy between our 
knowledge, attitude and practice.
Obesity is the new epidemic and it is estimated that > 
25% of children and adults in Western Countries are 
overweight (BMI ≥ 25 kg/m2). Of sure, lack of physical 
exercise and sedentary life are the main causes of the 
obesity epidemic. Junk food and lack of consumption of 
green vegetables and fresh fruits augment the problem. 
Obesity, lack of physical exercise, sedentary life, junk 
food and low consumption of green vegetables and fresh 
fruits are well-known cancer risk factors [2].
It is clear that we look for health but we are not ready to 
adopt measures for getting better health. It is much eas-
ier to swallow tablets or capsules to get more healthy. 
Intramuscular injections with all types of vaccines 
are more comfortable than using protective measures 
against blood borne and sexually transmitted diseases. 
Quitting smoking is not that easy meanwhile one daily 
table of antioxidants is very easy. We do not want to 
control our diet and prefer junk food. We can enjoy see-
ing the television instead of going out to the park and 
run after nothing.
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